{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-06T10:37:23.454502+00:00","company":{"ticker":"NAGE","cik":1386570,"company_name":"Niagen Bioscience, Inc."},"pagination":{"limit":100,"returned":9,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"28079bd6b371846ae571376be4f336622967664f","cik":1386570,"ticker":"NAGE","company_name":"Niagen Bioscience, Inc.","filed_at":"2026-05-06T23:59:59+00:00","payload":{"eps_text":"$0.08 and $0.07, respectively","guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":"$6.3 million","period_text":"first quarter of 2026","report_date":"2026-05-06","result_type":"reported_results","revenue_text":"$31.5 million"},"claim":"Niagen Bioscience, Inc. reported first quarter of 2026 results: revenue $31.5 million, net income $6.3 million, EPS $0.08 and $0.07, respectively. Guidance reaffirmed.","evidence_excerpt":"Niagen Bioscience, Inc. Reports First Quarter 2026 Financial Results Net sales increased to $31.5 million Gross margin improved to 63.5% Net income of $6.3 million, up $1.3 million from the prior year and adjusted EBITDA of $3.8 million LOS ANGELES, CA - May 6, 2026 - Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced financial results for the first quarter of 2026.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001386570-26-000031","anchor_url":"https://secwatch.observer/filing/0001386570-26-000031#claim-28079bd6b371846ae571376be4f336622967664f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1386570/000138657026000031/0001386570-26-000031-index.htm"},{"fact_type":"executive_change","fact_key":"b0825339e7","cik":1386570,"ticker":"NAGE","company_name":"Niagen Bioscience, Inc.","filed_at":"2024-09-20T23:59:59+00:00","payload":{"action":"replaced","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2024-10-21","interim":false,"role":"Controller","role_category":"other_named_officer","successor_name":"Ozan Pamir","successor_named":true},"claim":"James Lee changed role as Controller at Niagen Bioscience, Inc..","evidence_excerpt":"Mr. Pamir will replace James Lee, who is currently serving as the Company’s Interim Chief Financial Officer and Interim Principal Accounting Officer.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001628280-24-040982","anchor_url":"https://secwatch.observer/filing/0001628280-24-040982#claim-b0825339e7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1386570/000162828024040982/0001628280-24-040982-index.htm"},{"fact_type":"executive_change","fact_key":"93a8c2c17a","cik":1386570,"ticker":"NAGE","company_name":"Niagen Bioscience, Inc.","filed_at":"2024-09-20T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-10-21","interim":false,"role":"Chief Financial Officer and Principal Accounting Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Ozan Pamir was appointed as Chief Financial Officer and Principal Accounting Officer at Niagen Bioscience, Inc..","evidence_excerpt":"On September 19, 2024, the Board of Directors (the “Board”) of ChromaDex Corporation (the “Company” or “ChromaDex”) appointed Ozan Pamir as the Company’s Chief Financial Officer and Principal Accounting Officer, effective as of October 21, 2024","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001628280-24-040982","anchor_url":"https://secwatch.observer/filing/0001628280-24-040982#claim-93a8c2c17a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1386570/000162828024040982/0001628280-24-040982-index.htm"},{"fact_type":"executive_change","fact_key":"cd7d9f39e9","cik":1386570,"ticker":"NAGE","company_name":"Niagen Bioscience, Inc.","filed_at":"2024-07-16T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-07-13","interim":true,"role":"Interim Chief Financial Officer and Interim Principal Accounting Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"James Lee was appointed as Interim Chief Financial Officer and Interim Principal Accounting Officer at Niagen Bioscience, Inc..","evidence_excerpt":"On July 16, 2024, the Board of Directors (the “Board”) of ChromaDex Corporation (the “Company” or “ChromaDex”) appointed James Lee, the Company’s current Controller, as the Company’s Interim Chief Financial Officer and Interim Principal Accounting Officer, effective as of July 13, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001628280-24-031955","anchor_url":"https://secwatch.observer/filing/0001628280-24-031955#claim-cd7d9f39e9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1386570/000162828024031955/0001628280-24-031955-index.htm"},{"fact_type":"executive_change","fact_key":"ff8218be56","cik":1386570,"ticker":"NAGE","company_name":"Niagen Bioscience, Inc.","filed_at":"2024-07-16T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-07-12","interim":false,"role":"Chief Financial Officer and Principal Accounting Officer","role_category":"cfo","successor_name":"James Lee","successor_named":true},"claim":"Brianna Gerber resigned as Chief Financial Officer and Principal Accounting Officer at Niagen Bioscience, Inc..","evidence_excerpt":"As previously disclosed, Brianna Gerber resigned from her roles as the Company’s Chief Financial Officer and Principal Accounting Officer effective July 12, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001628280-24-031955","anchor_url":"https://secwatch.observer/filing/0001628280-24-031955#claim-ff8218be56","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1386570/000162828024031955/0001628280-24-031955-index.htm"},{"fact_type":"executive_change","fact_key":"53922cea66","cik":1386570,"ticker":"NAGE","company_name":"Niagen Bioscience, Inc.","filed_at":"2024-06-25T23:59:59+00:00","payload":{"action":"resigning","action_category":"departure","departure_tone":"routine","effective_date":"2024-07-12","interim":false,"role":"Chief Financial Officer and Chief Accounting Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Brianna Gerber departed as Chief Financial Officer and Chief Accounting Officer at Niagen Bioscience, Inc..","evidence_excerpt":"On June 19, 2024, Brianna Gerber, the Chief Financial Officer and Chief Accounting Officer of ChromaDex Corporation (the “Company”), informed the Company that she will be resigning from her roles with the Company, effective July 12, 2024 (the “Separation Date”).","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001628280-24-029936","anchor_url":"https://secwatch.observer/filing/0001628280-24-029936#claim-53922cea66","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1386570/000162828024029936/0001628280-24-029936-index.htm"},{"fact_type":"earnings_release","fact_key":"b879660f94e7f07e0a4d18a2369d3b575dba14cf","cik":1386570,"ticker":"NAGE","company_name":"Niagen Bioscience, Inc.","filed_at":"2024-05-08T23:59:59+00:00","payload":{"eps_text":"$(0.01) per share","guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":"$0.5 million","period_text":"first quarter of 2024","report_date":"2024-05-08","result_type":"reported_results","revenue_text":"$22.2 million"},"claim":"Niagen Bioscience, Inc. reported first quarter of 2024 results: revenue $22.2 million, net income $0.5 million, EPS $(0.01) per share. Guidance reaffirmed.","evidence_excerpt":"ChromaDex Corporation Reports First Quarter 2024 Financial Results Total net sales of $22.2 million, gross margin of 60.7%, a net loss of $0.5 million and a positive Adjusted EBITDA of $0.7 million for the three months ended March 31, 2024. Reiterated full year outlook including net sales growth of at least 16%.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-24-021648","anchor_url":"https://secwatch.observer/filing/0001628280-24-021648#claim-b879660f94e7f07e0a4d18a2369d3b575dba14cf","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1386570/000162828024021648/0001628280-24-021648-index.htm"},{"fact_type":"earnings_release","fact_key":"f23a4db9159eda1e1c34f074edfba341bf500d14","cik":1386570,"ticker":"NAGE","company_name":"Niagen Bioscience, Inc.","filed_at":"2024-03-06T23:59:59+00:00","payload":{"eps_text":"$0.07 loss per share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"net loss of only $4.9 million","period_text":"Fiscal Year 2023","report_date":"2024-03-06","result_type":"reported_results","revenue_text":"$83.6 million"},"claim":"Niagen Bioscience, Inc. reported Fiscal Year 2023 results: revenue $83.6 million, net income net loss of only $4.9 million, EPS $0.07 loss per share.","evidence_excerpt":"Full year net sales of $83.6 million, up 16% from the prior year, gross margin of 60.8%, net loss of only $4.9 million, positive Adjusted EBITDA of $1.9 million and positive operating cash flows.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-24-009383","anchor_url":"https://secwatch.observer/filing/0001628280-24-009383#claim-f23a4db9159eda1e1c34f074edfba341bf500d14","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1386570/000162828024009383/0001628280-24-009383-index.htm"},{"fact_type":"earnings_release","fact_key":"a0ba39853b260dceaa36249e0d5a5572d3173abf","cik":1386570,"ticker":"NAGE","company_name":"Niagen Bioscience, Inc.","filed_at":"2024-03-06T23:59:59+00:00","payload":{"eps_text":"$0.00 earnings per share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"net income of $0.1 million","period_text":"Fourth Quarter 2023","report_date":"2024-03-06","result_type":"reported_results","revenue_text":"$21.2 million"},"claim":"Niagen Bioscience, Inc. reported Fourth Quarter 2023 results: revenue $21.2 million, net income net income of $0.1 million, EPS $0.00 earnings per share.","evidence_excerpt":"Fourth quarter net sales of $21.2 million, gross margin of 61.0%, and net income of $0.1 million.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-24-009383","anchor_url":"https://secwatch.observer/filing/0001628280-24-009383#claim-a0ba39853b260dceaa36249e0d5a5572d3173abf","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1386570/000162828024009383/0001628280-24-009383-index.htm"}]}